Pacira BioSciences has bolstered its intellectual property portfolio by securing a new U.S. patent for its flagship pain therapy, EXPAREL. This latest achievement marks the inception of a new patent family stemming from the company’s advanced manufacturing process, ensuring protection for the innovative composition until July 2044. The patent, titled “Manufacturing of Bupivacaine Multivesicular Liposomes,” underscores Pacira’s dedication to sustaining its market leadership in non-opioid pain management solutions.
Enhancing Intellectual Property Portfolio
The newly obtained U.S. Patent No. 12,156,940 expands Pacira’s existing EXPAREL intellectual property, following the FDA approval of the enhanced large-scale manufacturing process in February 2024. Frank D. Lee, Pacira’s CEO, highlighted that this patent strengthens the company’s strategy to maintain a robust IP portfolio, providing comprehensive protection for EXPAREL across multiple dimensions. This strategic move not only prolongs the commercial viability of EXPAREL but also fortifies Pacira’s competitive edge in the pharmaceutical industry.
Legal Actions to Defend Market Position
In addition to expanding its patent holdings, Pacira is actively pursuing legal measures to safeguard its products. The company plans to file a patent infringement lawsuit against Jiangsu Hengrui Pharmaceuticals Co. LTD. and Fresenius Kabi USA, LLC. Furthermore, ongoing litigation includes a case against eVenus Pharmaceutical Laboratories, Inc., Jiangsu Hengrui, and Fresenius for infringing upon previous patents. These legal actions demonstrate Pacira’s commitment to defending its innovations and ensuring the exclusive market presence of its non-opioid pain therapies.
- Extended patent protection ensures market exclusivity for EXPAREL until 2044.
- New patent family reinforces Pacira’s manufacturing capabilities and innovation.
- Legal proceedings aim to prevent competitors from infringing on Pacira’s IP rights.
- Expanded IP portfolio supports long-term strategic growth and investment in R&D.
Pacira’s strategic acquisition of new patents and proactive legal stance not only secures its current market position but also paves the way for future advancements in pain management therapies. By maintaining a strong intellectual property foundation, Pacira is well-positioned to innovate and meet the evolving needs of patients, ultimately enhancing its role as a leader in non-opioid pain solutions.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
